nach oben

American Journal of Clinical Dermatology

Erschienen in:

11.01.2021 | Therapy in Practice

Management of Difficult-to-Treat Warts: Traditional and New Approaches

verfasst von: Peter C. Friedman

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Warts are regularly treated by dermatologists, and while many respond readily to first-line treatments, others may represent a therapeutic challenge. Large, deep, numerous, and extensive warts; treatment-resistant lesions with higher risk for side effects, such as hypopigmentation; or patients unable to tolerate or comply with our treatment regimen, may need alternative treatment options. In this work we review the characteristics of select modalities that should be considered for difficult-to-treat warts. We discuss efficacy and tolerability data as well as practical features that can guide us to select the best treatment for every scenario. Novel approaches, still in an investigational phase, are also discussed to illustrate potential future directions of wart treatment.

Van Haalen FM, Bruggink SC, Gussekloo J, Assendelft WJJ, Eekhof JAH. Warts in primary schoolchildren: prevalence and relation with environmental factors. Br J Dermatol. 2009;161(1):148–52. https://doi.org/10.1111/j.1365-2133.2009.09160.x.CrossRefPubMed

Boull C, Groth D. Update: treatment of cutaneous viral warts in children. Pediatr Dermatol. 2011;28(3):217–29. https://doi.org/10.1111/j.1525-1470.2010.01378.x.CrossRefPubMed

Lim HW, Collins SAB, Resneck JS, et al. The burden of skin disease in the United States. J Am Acad Dermatol. 2017;76(5):958-972.e2. https://doi.org/10.1016/j.jaad.2016.12.043.CrossRefPubMed

Clifton MM, Johnson SM, Roberson PK, Kincannon J, Horn TD. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol. 2003;20(3):268–71. https://doi.org/10.1046/j.1525-1470.2003.20318.x.CrossRefPubMed

Lipke MM. An armamentarium of wart treatments. Clin Med Res. 2006;4(4):273–93. https://doi.org/10.3121/cmr.4.4.273.CrossRefPubMedPubMedCentral

Spira R, Mignard M, Doutre MS, Morlat P, Dabis F. Prevalence of cutaneous disorders in a population of HIV-infected patients: Southwestern France, 1996. Arch Dermatol. 1998;134(10):1208–12. https://doi.org/10.1001/archderm.134.10.1208.CrossRefPubMed

Ahn CS, Huang WW. Imiquimod in the treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol. 2014;15(5):387–99. https://doi.org/10.1007/s40257-014-0093-5.CrossRefPubMed

Cobb MW. Human papillomavirus infection. J Am Acad Dermatol. 1990;22(4):547–66. https://doi.org/10.1016/0190-9622(90)70073-Q.CrossRefPubMed

Kwok CS, Gibbs S, Bennett C, Holland R, Abbott R. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.CD001781.pub3.CrossRefPubMed

10.

Kirtschig G. What are the benefits and harms of topical treatments in people with cutaneous warts? Cochrane clinical answers. Wiley; 2014. https://doi.org/10.1002/cca.468

11.

Nguyen AL, Quint KD, Bouwes Bavinck JN, Erceg A, de Kort WJA, Körver JEM. Real-life treatment of cutaneous warts with cantharidin podophyllin salicylic acid solution. Dermatol Ther. 2019;32(6):1–7. https://doi.org/10.1111/dth.13143.CrossRef

12.

Kaçar N, Taşli L, Korkmaz S, Ergin Ş, Erdoǧan BŞ. Cantharidin-podophylotoxin-salicylic acid versus cryotherapy in the treatment of plantar warts: a randomized prospective study. J Eur Acad Dermatology Venereol. 2012;26(7):889–93. https://doi.org/10.1111/j.1468-3083.2011.04186.x.CrossRef

13.

Dall’Oglio F, D’Amico V, Nasca MR, Micali G. Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol. 2012;13(2):73–96. https://doi.org/10.2165/11594610-000000000-00000.CrossRefPubMed

14.

Johnson SM, Roberson PK, Horn TD. Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol. 2001;137:451–5.PubMed

15.

Khozeimeh F, Jabbari Azad F, Mahboubi Oskouei Y, et al. Intralesional immunotherapy compared to cryotherapy in the treatment of warts. Int J Dermatol. 2017;56(4):474–8. https://doi.org/10.1111/ijd.13535.CrossRefPubMed

16.

Muñoz Garza FZ, Roé Crespo E, Torres Pradilla M, et al. Intralesional Candida antigen immunotherapy for the treatment of recalcitrant and multiple warts in children. Pediatr Dermatol. 2015;32(6):797–801. https://doi.org/10.1111/pde.12667.CrossRefPubMed

17.

Signore RJ. Candida albicans intralesional injection immunotherapy of warts. Cutis. 2002;70(3):185–92.PubMed

18.

Majid I, Imran S. Immunotherapy with intralesional Candida albicans antigen in resistant or recurrent warts: a study. Indian J Dermatol. 2013;58(5):360–5. https://doi.org/10.4103/0019-5154.117301.CrossRefPubMedPubMedCentral

19.

Maronn M, Salm C, Lyon V, Galbraith S. One-year experience with candida antigen immunotherapy for warts and molluscum. Pediatr Dermatol. 2008;25(2):189–92. https://doi.org/10.1111/j.1525-1470.2008.00630.x.CrossRefPubMed

20.

Attwa E, Elawady R, Salah E. ‘Cryo-immuno-therapy’ is superior to intralesional Candida antigen monotherapy in the treatment of multiple common warts. J Dermatol Treat. 2020. https://doi.org/10.1080/09546634.2020.1720585.CrossRef

21.

Hodeib AAE, Al-Sharkawy BG, Hegab DS, Talaat RAZ. A comparative study of intralesional injection of Candida albicans antigen, bleomycin and 5-fluorouracil for treatment of plane warts. J Dermatol Treat. 2019. https://doi.org/10.1080/09546634.2019.1688236.CrossRef

22.

Nofal A, Nofal E. Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol. 2010;24(10):1166–70. https://doi.org/10.1111/j.1468-3083.2010.03611.x.CrossRefPubMed

23.

Nofal A, Nofal E, Yosef A, Nofal H. Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach. Int J Dermatol. 2015;54(6):667–71. https://doi.org/10.1111/ijd.12480.CrossRefPubMed

24.

Na CH, Choi H, Song SH, Kim MS, Shin BS. Two-year experience of using the measles, mumps and rubella vaccine as intralesional immunotherapy for warts. Clin Exp Dermatol. 2014;39(5):583–9. https://doi.org/10.1111/ced.12369.CrossRefPubMed

25.

Pushpinder SC, Vikram KMKSM, Ritu Rawat VS, Department. The efficacy and safety of intralesional immunotherapy with measles, mumps, rubella virus vaccine for the treatment of common warts in adults abstract. Indian Dermatol Online J. 2019;10(1):19–26. https://doi.org/10.4103/idoj.IDOJ.

26.

Chesta A, Kapil VAM, Ashok KKLKG, Department. A randomized double blind controlled study comparing the efficacy of intralesional MMR vaccine with normal saline in the treatment of cutaneous warts abstract. Dermatol Online J. 218AD;9(6):390–393. https://doi.org/10.4103/idoj.IDOJ.

27.

Mobasher P, Zamanian A. Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart. Adv Biomed Res. 2014;3(1):107. https://doi.org/10.4103/2277-9175.129701.CrossRefPubMedPubMedCentral

28.

Abd El-Magiud EM, Abd El-Samea GM, Gaber HD. Intralesional injection of measles, mumps, and rubella vaccine versus cryotherapy in treatment of warts: a randomized controlled trial. Dermatol Ther. 2020;33(2):1–7. https://doi.org/10.1111/dth.13257.CrossRef

29.

Shaheen MA, Salem SAM, Fouad DA, El-Fatah AAA. Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study. Dermatol Ther. 2015;28(4):194–200. https://doi.org/10.1111/dth.12230.CrossRefPubMed

30.

Yang MY, Son JH, Kim GW, et al. Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients. J Dermatolog Treat. 2019;30(4):405–9. https://doi.org/10.1080/09546634.2018.1527006.CrossRefPubMed

31.

Ling YK. Human papillomavirus vaccine for the treatment of recalcitrant extragenital warts. J Am Acad Dermatol. 2017;76(6):159. https://doi.org/10.1016/j.jaad.2017.04.617.CrossRef

32.

Nofal A, Marei A, Ibrahim A, Shimaa M, Nofal E, Nabil M. Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts. J Am Acad Dermatol. 2019;82(1):94–100. https://doi.org/10.1016/j.jaad.2019.07.070.CrossRefPubMed

33.

Ferguson SB, Gallo ES. Nonavalent human papillomavirus vaccination as a treatment for warts in an immunosuppressed adult. JAAD Case Rep. 2017;3(4):367–9. https://doi.org/10.1016/j.jdcr.2017.05.007.CrossRefPubMedPubMedCentral

34.

Kost Y, Zhu TH, Blasiak RC. Clearance of recalcitrant warts in a pediatric patient following administration of the nine-valent human papillomavirus vaccine. Pediatr Dermatol. 2020;37(4):748–9. https://doi.org/10.1111/pde.14150.CrossRefPubMed

35.

Bossart S, Imstepf V, Hunger RE, Seyed Jafari SM. Nonavalent human papillomavirus vaccination as a treatment for skin warts in immunosuppressed adults: a case series. Acta Dermatol Venereol. 2020;100(6):1–2. https://doi.org/10.2340/00015555-3437.CrossRef

36.

Kerure AS, Nath AK, Oudeacoumar P. Intralesional immunotherapy with tuberculin purified protein derivative for verruca: a study from a teaching hospital in South India. Indian J Dermatol Venereol Leprol. 2016;82(4):420–2. https://doi.org/10.4103/0378-6323.175910.CrossRefPubMed

37.

Amirnia M, Khodaeiani E, Fouladi DF, Masoudnia S. Intralesional immunotherapy with tuberculin purified protein derivative (PPD) in recalcitrant wart: a randomized, placebo-controlled, double-blind clinical trial including an extra group of candidates for cryotherapy. J Dermatol Treat. 2016;27(2):173–8. https://doi.org/10.3109/09546634.2015.1078871.CrossRef

38.

Gupta S, Singh S, Chouhan K. Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts. Indian J Dermatol Venereol Leprol. 2014;80(6):509. https://doi.org/10.4103/0378-6323.144145.CrossRefPubMed

39.

Garg S, Baveja S. Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine. J Cutan Aesthet Surg. 2014;7(4):203. https://doi.org/10.4103/0974-2077.150740.CrossRefPubMedPubMedCentral

40.

Al-Mendalawi MD, Sharquie K. Bacille Calmette–Guerin immunotherapy of viral warts. Saudi Med J. 2008;29(4):589–93.

41.

Jaisinghani A, Dey V, Suresh M, Saxena A. Bacillus Calmette–Guerin immunotherapy for recurrent multiple warts: an open-label uncontrolled study. Indian J Dermatol. 2019;64(2):164. https://doi.org/10.4103/ijd.IJD_558_16.CrossRefPubMedPubMedCentral

42.

Chia-Han Yeh M, Tsai T, Huang Y. Intralesional vitamin D3 injection in the treatment of warts: a systematic review and meta-analysis. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2019.10.059.CrossRefPubMed

43.

Raghukumar S, Ravikumar BC, Vinay KN, Suresh MR, Aggarwal A, Yashovardhana DP. Intralesional vitamin D3 injection in the treatment of recalcitrant warts: a novel proposition. J Cutan Med Surg. 2017;21(4):320–4. https://doi.org/10.1177/1203475417704180.CrossRefPubMed

44.

Priya A, Adil M, Amin SS, Mohtashim M, Bansal R, Alam M. Intralesional vitamin D3 in recalcitrant palmoplantar and periungual warts: a prospective, observational study. Acta Dermatovenerologica Croat. 2019;27(4):215–24.

45.

Kareem IMA, Ibrahim IM, Mohammed SFF, Ahmed AAB. Effectiveness of intralesional vitamin D3 injection in the treatment of common warts: single-blinded placebo-controlled study. Dermatol Ther. 2019;32(3):1–3. https://doi.org/10.1111/dth.12882.CrossRef

46.

Fathy G, Sharara MA, Khafagy AH. Intralesional vitamin D3 versus Candida antigen immunotherapy in the treatment of multiple recalcitrant plantar warts: a comparative case–control study. Dermatol Ther. 2019;32(5):1–5. https://doi.org/10.1111/dth.12997.CrossRef

47.

Mohta A, Kushwaha RK, Gautam U, Sharma P, Nyati A, Jain SK. A comparative study of the efficacy and safety of intralesional measles, mumps, and rubella vaccine versus intralesional vitamin D3 for the treatment of warts in children. Pediatr Dermatol. 2020. https://doi.org/10.1111/pde.14280.CrossRefPubMed

48.

Imagawa I, Suzuki H. Successful treatment of refractory warts with topical vitamin D3 derivative (maxacalcitol,1α,25-dihydroxy-22-oxacalcitriol) in 17 patients. J Dermatol. 2007;34(4):264–6. https://doi.org/10.1111/j.1346-8138.2007.00266.x.CrossRefPubMed

49.

Egawa KOT. Topical vitamin D3derivatives for recalcitrant warts inthree immunocompromised patients. Br J Dermatol. 2004;2(150):374–6.CrossRef

50.

Rind T, Oiso N, Kawada A. Successful treatment of aanogenital wart with a topical vitamin D3 derivative in an infant. Case Rep Dermatol. 2010;2(1):46–9. https://doi.org/10.1159/000312986.CrossRefPubMedPubMedCentral

51.

Labandeira J, Vázquez-Blanco M, Paredes C, Suárez-Peñaranda JM, Toribio J. Efficacy of topical calcipotriol in the treatment of a giant viral wart. Pediatr Dermatol. 2005;22(4):375–6. https://doi.org/10.1111/j.1525-1470.2005.22425.x.CrossRefPubMed

52.

Zabawski J, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol. 1998;39(5 I):741–5. https://doi.org/10.1016/s0190-9622(98)70046-5.CrossRefPubMed

53.

Zabawski EJ, Sands B, Goetz D, Naylor M, Cockerell CJ. Treatment of verruca vulgaris with topical cidofovir. J Am Med Assoc. 1997;278(15):1236. https://doi.org/10.1001/jama.1997.03550150040032.CrossRef

54.

Broganelli P, Chiaretta A, Fragnelli B, Bernengo MG. Intralesional cidofovir for the treatment of multiple and recalcitrant cutaneous viral warts. Dermatol Ther. 2012;25(5):468–71. https://doi.org/10.1111/j.1529-8019.2012.01477.x.CrossRefPubMed

55.

Anshelevich EE, Barbieri JS, Kovarik CL. Intralesional cidofovir for treatment of recalcitrant warts in both immunocompetent and immunocompromised patients: a retrospective analysis of 58 patients. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.118.CrossRefPubMed

56.

Field S, Irvine AD, Kirby B. The treatment of viral warts with topical cidofovir 1%: our experience of seven paediatric patients. Br J Dermatol. 2009;160(1):223–4. https://doi.org/10.1111/j.1365-2133.2008.08947.x.CrossRefPubMed

57.

Fernandez-Morano TJB, Gonzalez-Carrascosa M, Tortajada BMT. Topical cidofovir for viral warts in children. J Eur Acad Dermatol Venereol. 2011;25(12):1487–9. https://doi.org/10.1111/j.1468-3083.2010.03949.x.CrossRefPubMed

58.

España LP, Del Boz J, Fernández Morano T, Arenas-Villafranca J, De Troya M. Successful treatment of periungual warts with topical cidofovir. Dermatol Ther. 2014;27(6):337–42. https://doi.org/10.1111/dth.12161.CrossRef

59.

Muffarrej D, Khattab E, Najjar R. Successful treatment of genital warts with cidofovir cream in a pediatric patient with Fanconi anemia. J Oncol Pharm Pract. 2019. https://doi.org/10.1177/1078155219886924.CrossRefPubMed

60.

Matteelli A, Beltrame A, Graifemberghi S, et al. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm Dis. 2001;28(6):343–6. https://doi.org/10.1097/00007435-200106000-00007.CrossRefPubMed

61.

Espana LP. Recalcitrant warts and topical cidofovir: predictive factors of good response. J Eur Acad Dermatol Venereol. 2016;30(7):1218–20. https://doi.org/10.1111/jdv.13142.CrossRef

62.

Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation. 2002;73(4):661–2. https://doi.org/10.1097/00007890-200202270-00033.CrossRefPubMed

63.

Nyberg WA, Espinosa A. Imiquimod induces ER stress and Ca²⁺ influx independently of TLR7 and TLR8. Biochem Biophys Res Commun. 2016;473(4):789–94. https://doi.org/10.1016/j.bbrc.2016.03.080.CrossRefPubMed

64.

Micali G, Dall’Oglio F, Nasca MR. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatol Treat. 2003;14(4):233–6. https://doi.org/10.1080/09546630310016763.CrossRef

65.

Thi Minh PP, Pham Thi L, Tran Lan A, et al. Early treatment with imiquimod 5% cream of periungual warts in Vietnam: the poorer, the better. Open Access Maced J Med Sci. 2019;7(2):214–6. https://doi.org/10.3889/oamjms.2019.053.CrossRef

66.

Stefanaki C, Lagogiani I, Kouris A, Kontochristopoulos G, Antoniou C, Katsarou A. Cryotherapy versus imiquimod 5% cream combined with a keratolytic lotion in cutaneous warts in children: a randomized study. J Dermatol Treat. 2016;27(1):80–2. https://doi.org/10.3109/09546634.2015.1034079.CrossRef

67.

Long FQ, Zhao LS, Qian YH. Vitiligo or vitiligo-like hypopigmentation associated with imiquimod treatment of condyloma acuminatum: not a casual event. Chin Med J (Engl). 2017;130(4):503–4. https://doi.org/10.4103/0366-6999.199846.CrossRefPubMedPubMedCentral

68.

Edgar N, Pilkington S, Hogan DJ. Imiquimod-induced hypopigmentation following treatment of periungual verruca vulgaris. Cutis. 2018;101(6):466–8. https://doi.org/10.1016/j.jaad.2015.02.207.CrossRefPubMed

69.

Abdo HM, Elrewiny EM, Elkholy MS, Ibrahim SM. Efficacy of intralesional methotrexate in the treatment of plantar warts. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13228.CrossRefPubMed

70.

Bik L, Sangers T, Greveling K, Prens E, Haedersdal M, van Doorn M. Efficacy and tolerability of intralesional bleomycin in dermatology: a systematic review. J Am Acad Dermatol. 2020;83(3):888–903. https://doi.org/10.1016/j.jaad.2020.02.018.CrossRefPubMed

71.

Abess A, Keel DM, Graham BS. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol. 2003. https://doi.org/10.1001/archderm.139.3.337.CrossRefPubMed

72.

Kaul S, Kaur I, Jakhar D. Intralesional bleomycin in cutaneous warts: does combining with lasers or electroporation confer additional benefit? J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.09.017.CrossRefPubMed

73.

Kaul S, Caldito EG, Jakhar D, Kaur I, Kwatra SG, Mehta S. Comparative efficacy and safety of intralesional bleomycin relative to topical bleomycin with microneedling in the treatment of warts: a systematic review. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.06.035.CrossRefPubMed

74.

Yazdanfar A, Farshchian M, Fereydoonnejad M, Farshchian M. Treatment of common warts with an intralesional mixture of 5-fluorouracil, lidocaine, and epinephrine: a prospective placebo-controlled, double-blind randomized trial. Dermatol Surg. 2008;34(5):656–9. https://doi.org/10.1111/j.1524-4725.2007.34123.x.CrossRefPubMed

75.

Hursthouse MW. A controlled trial on the use of topical 5-fluorouracil on viral warts. Br J Dermatol. 1975;92(1):93–6. https://doi.org/10.1111/j.1365-2133.1975.tb03039.x.CrossRefPubMed

76.

Gonçalves JCA. 5-Fluorouracil in the treatment of common warts of the hands: a double-blind study. Br J Dermatol. 1975;92(1):89–91. https://doi.org/10.1111/j.1365-2133.1975.tb03038.x.CrossRefPubMed

77.

Luk NM, Tang WYM, Tang NLS, et al. Topical 5-fluorouracil has no additional benefit in treating common warts with cryotherapy: a single-centre, double-blind, randomized, placebo-controlled trial. Clin Exp Dermatol. 2006;31(3):394–7. https://doi.org/10.1111/j.1365-2230.2006.02105.x.CrossRefPubMed

78.

Ghonemy S, Ibrahim Ali M, Ebrahim HM. The efficacy of microneedling alone vs its combination with 5-fluorouracil solution vs 5-fluorouracil intralesional injection in the treatment of plantar warts. Dermatol Ther. 2020;50(6):776–80. https://doi.org/10.1111/dth.14179.CrossRef

79.

Huang K, Li Y, Zeng W, et al. Successful treatment of recalcitrant plantar warts: pretreatment with superficial shaving is vital before photodynamic therapy. Photodiagn Photodyn Ther. 2019;27:216–7. https://doi.org/10.1016/j.pdpdt.2019.05.040.CrossRef

80.

Wu MF, Lv T, Miao F, Wang XL, Liu YQ, Wang HW. Periungual and subungual warts successfully treated with combination of electric shaving, curettage, and photodynamic therapy. Photodermatol Photoimmunol Photomed. 2020. https://doi.org/10.1111/phpp.12599.CrossRefPubMed

81.

Ibrahim NA, Abdel Fadeel DA, Sadek A, Fadel M, Tawfik A. Intralesional vitamin D3 versus new topical photodynamic therapy in recalcitrant palmoplanter warts randomized comparative controlled study. Photodiagn Photodyn Ther. 2020;32:101979. https://doi.org/10.1016/j.pdpdt.2020.101979.CrossRef

82.

Nassar A, Mostafa M, Khashaba SA. Photodynamic therapy versus candida antigen immunotherapy in plane wart treatment: a comparative controlled study. Photodiagn Photodyn Ther. 2020;32:101973. https://doi.org/10.1016/j.pdpdt.2020.101973.CrossRef

83.

Mizuki D, Kaneko T, Hanada K. Successful treatment of topical photodynamic therapy using 5-aminolevulinic acid for plane warts. Br J Dermatol. 2003;149(5):1087–8. https://doi.org/10.1111/j.1365-2133.2003.05617.x.CrossRefPubMed

84.

Borgia F, Coppola M, Giuffrida R, Cannavò SP. Excellent cosmetic result of daylight photodynamic therapy for facial flat warts in a child. Photodiagn Photodyn Ther. 2019;2019(26):27–8. https://doi.org/10.1016/j.pdpdt.2019.02.021.CrossRef

85.

Monfrecola G, Megna M, Rovati C, et al. A critical reappraisal of off-label use of photodynamic therapy for the treatment of non-neoplastic skin conditions. Dermatology. 2020. https://doi.org/10.1159/000507926.CrossRefPubMed

86.

Veitch D, Kravvas G, Al-Niaimi F. Pulsed dye laser therapy in the treatment of warts: a review of the literature. Dermatol Surg. 2017;43(4):485–93. https://doi.org/10.1097/DSS.0000000000001023.CrossRefPubMed

87.

Skeate JG, Da Silva DM, Chavez-Juan E, Anand S, Nuccitelli R, Martin KW. Nano-pulse stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response. PLoS ONE. 2018;13(1):1–17. https://doi.org/10.1371/journal.pone.0191311.CrossRef

88.

Nuccitelli R, Lui K, Kreis M, Athos B, Nuccitelli P. Nanosecond pulsed electric field stimulation of reactive oxygen species in human pancreatic cancer cells is Ca²⁺-dependent. Biochem Biophys Res Commun. 2013;435(4):580–5. https://doi.org/10.1016/j.bbrc.2013.05.014.CrossRefPubMedPubMedCentral

89.

Nuccitelli R. Nano-pulse stimulation therapy for the treatment of skin lesions. Bioelectricity. 2019;1(4):235–9. https://doi.org/10.1089/bioe.2019.0027.CrossRef

90.

Edward Lain MD, Brenda LaTowsky MD, Lesley Loss MDGMM. A prospective, non-randomized, multicenter pivotal study of nano-pulse stimulation (NPS) for treatment of cutaneous non-genital warts. In: American Society for Dermatologic Surgery, annual meeting; 2020.

91.

Nuccitelli R, Wood R, Kreis M, et al. First-in-human trial of nanoelectroablation therapy for basal cell carcinoma: proof of method. Exp Dermatol. 2014;23(2):135–7. https://doi.org/10.1111/exd.12303.CrossRefPubMedPubMedCentral

92.

Munavalli GS, Zelickson BD, Selim MM, et al. Safety and efficacy of nanosecond pulsed electric field treatment of sebaceous gland hyperplasia. Dermatol Surg. 2020;46(6):803–9. https://doi.org/10.1097/DSS.0000000000002154.CrossRefPubMed

93.

Hruza GJ, Zelickson BD, Selim MM, et al. Safety and efficacy of nanosecond pulsed electric field treatment of seborrheic keratoses. Dermatol Surg. 2020;46(9):1183–9. https://doi.org/10.1097/DSS.0000000000002278.CrossRefPubMed

94.

van Faassen EE, Bahrami S, Feelisch M, et al. Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res Rev. 2009;29(5):683–741. https://doi.org/10.1002/med.20151.CrossRefPubMedPubMedCentral

95.

Thakur NK, Hayashi T, Sumi D, et al. Anti-atherosclerotic effect of β-blocker with nitric oxide-releasing action on the severe atherosclerosis. J Cardiovasc Pharmacol. 2002;39(2):298–309. https://doi.org/10.1097/00005344-200202000-00017.CrossRefPubMed

96.

Kim PK, Zamora R, Petrosko P, Billiar TR. The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol. 2001;1(8):1421–41. https://doi.org/10.1016/S1567-5769(01)00088-1.CrossRefPubMed

97.

Ramachandran RA, Lupfer C, Zaki H. The inflammasome: regulation of nitric oxide and antimicrobial host defence. Adv Microb Physiol. 2018;72:65–115. https://doi.org/10.1016/bs.ampbs.2018.01.004.CrossRefPubMed

98.

Banerjee NS, Moore DW, Wang HK, Broker TR, Chow LT. NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions. Antivir Res. 2019;170(June):104559. https://doi.org/10.1016/j.antiviral.2019.104559.CrossRefPubMed

99.

Ormerod AD, Van Voorst Vader PC, Majewski S, Vanscheidt W, Benjamin N, Van Der Meijden W. Evaluation of the efficacy, safety, and tolerability of 3 dose regimens of topical sodium nitrite with citric acid in patients with anogenital warts: a randomized clinical trial. JAMA Dermatol. 2015;151(8):854–61. https://doi.org/10.1001/jamadermatol.2015.0381.CrossRefPubMed

100.

Tyring SK, Rosen T, Berman B, Stasko N, Durham T, Maeda-Chubachi T. A phase 2 controlled study of SB206, a topical nitric oxide-releasing drug for extragenital wart treatment. J Drugs Dermatol. 2018;17(10):1100–5.PubMed

101.

Hebert AA, Siegfried EC, Durham T, et al. Efficacy and tolerability of an investigational nitric oxide–releasing topical gel in patients with molluscum contagiosum: a randomized clinical trial. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2019.09.064.CrossRefPubMedPubMedCentral

102.

Chuangsuwanich A, Assadamongkol T, Boonyawan D. The healing effect of low-temperature atmospheric-pressure plasma in pressure ulcer: a randomized controlled trial. Int J Low Extrem Wounds. 2016;15(4):313–9. https://doi.org/10.1177/1534734616665046.CrossRefPubMed

103.

Friedman PC. Cold atmospheric pressure (physical) plasma in dermatology: where are we today? Int J Dermatol. 2020;59(10):1171–84. https://doi.org/10.1111/ijd.15110.CrossRefPubMed

104.

Von Woedtke T, Schmidt A, Bekeschus S, Wende K, Weltmann KD. Plasma medicine: a field of applied redox biology. In Vivo (Brooklyn). 2019;33(4):1011–26. https://doi.org/10.21873/invivo.11570.CrossRef

105.

Fridman G, Friedman G, Gutsol A, Shekhter AB, Vasilets VN, Fridman A. Applied plasma medicine. Plasma Process Polym. 2008;5(6):503–33. https://doi.org/10.1002/ppap.200700154.CrossRef

106.

von Woedtke T, Reuter S, Masur K, Weltmann KD. Plasmas for medicine. Phys Rep. 2013;530(4):291–320. https://doi.org/10.1016/j.physrep.2013.05.005.CrossRef

107.

Schneider C, Gebhardt L, Arndt S, et al. Cold atmospheric plasma causes a calcium influx in melanoma cells triggering CAP-induced senescence. Sci Rep. 2018;8(1):10048. https://doi.org/10.1038/s41598-018-28443-5.CrossRefPubMedPubMedCentral

108.

Zimmermann JL, Dumler K, Shimizu T, et al. Effects of cold atmospheric plasmas on adenoviruses in solution. J Phys D Appl Phys. 2011;44(50):505201. https://doi.org/10.1088/0022-3727/44/50/505201.CrossRef

109.

Bunz O, Mese K, Zhang W, Piwowarczyk A, Ehrhardt A. Effect of cold atmospheric plasma (CAP) on human adenoviruses is adenovirus typedependent. PLoS ONE. 2018;13(10):1–12. https://doi.org/10.1371/journal.pone.0202352.CrossRef

110.

Friedman PC, Miller V, Fridman G, Fridman A. Use of cold atmospheric pressure plasma to treat warts: a potential therapeutic option. Clin Exp Dermatol. 2019;44(4):459–61. https://doi.org/10.1111/ced.13790.CrossRefPubMed

111.

Friedman PC, Fridman G, Fridman A. Using cold plasma to treat warts in children: a case series. Pediatr Dermatol. 2020;37(4):706–9. https://doi.org/10.1111/pde.14180.CrossRefPubMed

112.

Friedman PC, Miller V, Fridman G, Lin A, Fridman A. Successful treatment of actinic keratoses using nonthermal atmospheric pressure plasma: a case series. J Am Acad Dermatol. 2017;76(2):349–50. https://doi.org/10.1016/j.jaad.2016.09.004.CrossRefPubMed

113.

Koch F, Salva KA, Wirtz M, et al. Efficacy of cold atmospheric plasma versus diclofenac 3% gel in patients with actinic keratoses: a prospective, randomized, and rater-blinded study (ACTICAP). J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16735.CrossRefPubMed

114.

Hartley C, Hartley M, Pardoe I, Knight A. Ionic contra-viral therapy (ICVT); a new approach to the treatment of DNA virus infections. Arch Virol. 2006;151(12):2495–501. https://doi.org/10.1007/s00705-006-0824-x.CrossRefPubMed

115.

van der Kolk T, Dillingh MR, Rijneveld R, et al. Topical ionic contra-viral therapy comprised of digoxin and furosemide as a potential novel treatment approach for common warts. J Eur Acad Dermatol Venereol. 2017;31(12):2088–90. https://doi.org/10.1111/jdv.14527.CrossRefPubMedPubMedCentral

116.

Rijsbergen M, Niemeyer-van der Kolk T, Hogendoorn G, et al. A randomized controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts. Br J Dermatol. 2019;180(5):1058–68. https://doi.org/10.1111/bjd.17583.CrossRefPubMedPubMedCentral

117.

Rijsbergen M, Rijneveld R, Todd M, et al. No effect of topical digoxin and furosemide gel for patients with external anogenital warts. J Eur Acad Dermatol Venereol. 2020;34(1):e45–6. https://doi.org/10.1111/jdv.15894.CrossRefPubMed

Titel: Management of Difficult-to-Treat Warts: Traditional and New Approaches
verfasst von: Peter C. Friedman
Publikationsdatum: 11.01.2021
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 3/2021
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-020-00582-4

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial

Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges

Dermatitis Herpetiformis: An Update on Diagnosis and Management

HLA-Cw1 and Psoriasis

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma